Bionano Genomics, Inc. (BNGO) Stock Forecast
BNGO analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 2 analysts
- Price target
- $5.00 average of analyst targets
- Upside to target
- +300.0% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.56
- 52-week range
- $1.06 – $1.98
BNGO analyst ratings
2 analystsNumber of analysts at each rating.
BNGO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BNGO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.45 | −$0.45 | −$0.45 | −$1.59 | +71.7% | 1 |
| Current fiscal year (2026) | −$2.14 | −$2.14 | −$2.14 | −$4.82 | +55.6% | 1 |
| Next fiscal year (2027) | −$0.97 | −$0.97 | −$0.97 | −$2.14 | +54.7% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BNGO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $8.4M | $8.4M | $8.4M | +14.3% | 2 |
| Current fiscal year (2026) | $32.1M | $31.8M | $32.5M | +12.7% | 2 |
| Next fiscal year (2027) | $43.3M | $43.3M | $43.3M | +34.7% | 1 |
BNGO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BNGO revenue: reported and forecast
BNGO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.54 | −$0.42 | −$0.42 | −$0.42 | −$0.45 | −16.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.71 | −$2.13 | −$2.13 | −$2.13 | −$2.14 | −21.0% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.11 | −$0.97 | −$0.97 | −$0.97 | −$0.97 | −12.6% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BNGO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BNGO beat in 8 of 12.
What analysts expect from BNGO
2 analysts cover Bionano Genomics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.00, 300.0% above the latest close of $1.25. Analysts expect earnings of −$2.14 per share for 2026, +55.6% from a year earlier. For 2027 the average estimate is −$0.97 per share on revenue of $43.3 million. Bionano Genomics beat the EPS estimate in 8 of the last 12 quarters.
Related: BNGO income statement, BNGO key metrics, BNGO chart. See the BNGO stock overview for the latest quote and news.
BNGO forecast FAQ
What is Bionano Genomics's price target?
The average analyst price target for Bionano Genomics is $5.00, 300.0% above the latest close of $1.25.
Is Bionano Genomics a buy, hold or sell?
Of 2 analysts covering Bionano Genomics, 1 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Bionano Genomics's EPS forecast?
Analysts forecast −$2.14 per share for 2026 (range −$2.14 to −$2.14); for 2027 the estimate is −$0.97.
What is Bionano Genomics's revenue forecast?
The average revenue estimate for 2026 is $32.1 million, growth of 12.7%; for 2027 it is $43.3 million.
When does Bionano Genomics report earnings?
Bionano Genomics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.56.
Does Bionano Genomics usually beat earnings estimates?
Bionano Genomics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.